SELLAS Life Sciences Soars 14.21% on Key Appointment

On July 10, 2025, SELLAS Life Sciences experienced a significant surge, rising 14.21% in pre-market trading, reflecting a strong investor sentiment towards the company's recent developments.

SELLAS Life Sciences has recently appointed Linghua Wang, MD, PhD, to its Scientific Advisory Board. This strategic move is expected to enhance the company's scientific expertise and strengthen its research and development capabilities. Dr. Wang's extensive background in oncology and immunology is anticipated to bring valuable insights and contributions to SELLAS Life Sciences' ongoing projects.

This appointment comes at a pivotal time for SELLAS Life Sciences, as the company continues to advance its pipeline of innovative therapies. The addition of Dr. Wang to the Scientific Advisory Board is seen as a positive step towards achieving the company's goals in the biotech sector, potentially driving further growth and innovation.